The study is designed to continue treatment for patients who have already participated in previous research with rocatinlimab. Participants will receive either rocatinlimab or placebo through injections under the skin. This is a long-term study that will monitor how well patients maintain improvement in their skin condition and any side effects that may occur during treatment.

The research will track various aspects of the skin condition, including changes in skin appearance, itching severity, and overall symptoms. The study will particularly focus on monitoring the safety of the treatment by recording any side effects and checking laboratory test results and vital signs throughout the treatment period.

Participants are randomly assigned to receive either the combination therapy or a single oral drug, and treatment continues until disease progression or unacceptable side effects occur. Visits include regular health checks, blood tests, and imaging scans to monitor the tumor and overall health. The study follows patients for several months to record how long they live, how long the disease stays stable, and any side effects that arise.

The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

The medication used in this procedure is bleomycin sulfate, which is administered as a solution for injection. During the study, participants undergo the treatment, and their progress is monitored over time. This includes using MRI, a type of imaging that uses magnetic fields to create detailed pictures of the body, to check for changes in the size of the affected area. The follow-up periods occur at three months and twelve months after the procedure to evaluate how well the treatment worked and to monitor any side effects.

Participants in this trial will receive either the study drug, remibrutinib, in the form of a film-coated tablet taken by mouth, or a placebo. The purpose of the study is to determine if this treatment can help delay the progression of disability. During the study, individuals will be monitored over a period of time to observe how the medication affects their physical abilities and overall health.

The purpose of the study is to assess how Dazodalibep affects the systemic manifestations, or widespread symptoms, of Sjögren’s Syndrome in participants who have moderate-to-severe disease activity. Participants in the study will receive either Dazodalibep or a placebo over a period of time, and their health will be monitored to observe any changes in their condition. The study will last for several weeks, and participants will undergo regular assessments to track their progress and any side effects they may experience.

Throughout the study, researchers will collect data on various health indicators, such as changes in disease activity scores and other symptoms related to Sjögren’s Syndrome. This information will help determine the potential benefits and risks of using Dazodalibep as a treatment option for this condition. The study is designed to provide valuable insights into the management of Sjögren’s Syndrome and to explore new possibilities for improving the quality of life for those affected by this disease.

The purpose of the study is to assess how well Dazodalibep works in reducing the symptoms of Sjögren’s Syndrome in people who experience moderate to severe symptoms. Participants in the study will receive either the treatment or a placebo, which is a substance with no active medication. The study will last for several weeks, during which participants will have regular check-ups to monitor their symptoms and overall health.

Throughout the study, participants will be asked to report on their symptoms and any changes they experience. The goal is to determine if Dazodalibep can provide relief from the symptoms of Sjögren’s Syndrome and to ensure that it is safe for use. The study will help researchers understand the potential benefits and any side effects of the treatment.

The purpose of this study is to show whether empasiprubart works better than human normal immunoglobulin in improving the ability to perform daily activities in adults with this nerve condition. During the study, participants will be randomly assigned to receive either empasiprubart or human normal immunoglobulin through a vein. The study uses a double-dummy design, which means that all participants will receive two infusions to ensure that neither the participants nor the doctors know which treatment is being given. The main assessment will happen at week 24, when doctors will measure changes in functional ability using a scoring system that evaluates arm and leg function.

Throughout the study, various measurements will be taken to assess how well participants can perform daily tasks, their muscle strength, their walking ability, and their overall quality of life. Grip strength will be measured regularly, and participants will complete questionnaires about their disability, fatigue, pain, and general health status. Blood samples will be taken to measure drug levels and to check for any immune responses to the treatment. Safety will be monitored by tracking any unwanted effects, changes in laboratory tests, heart rhythm recordings, and vital signs. The study will also look at how the treatments affect specific proteins in the blood that are involved in the immune response and nerve damage.

This is an extension study, which means it is designed for people who have already participated in and completed earlier studies of dazodalibep for Sjögren’s Syndrome. Those who join this study will continue to receive dazodalibep treatment for a longer time so that researchers can observe how safe the medication is when used over many months or years. The study will track any unwanted effects that occur during treatment, including any serious health problems that might develop. Researchers will also check if the body develops any immune responses against the medication by looking for anti-drug antibodies, which are proteins the body might make in reaction to the treatment.

Throughout the study, blood samples will be collected to measure the amount of dazodalibep in the bloodstream, which helps researchers understand how the medication moves through and stays in the body. The study is open-label, meaning both the participants and doctors will know that everyone is receiving the active medication rather than placebo. This long-term study allows researchers to gather important information about the ongoing safety of dazodalibep in people with Sjögren’s Syndrome over an extended treatment period.

The main goal of the study is to see how well CagriSema works at lowering blood sugar levels compared to semaglutide alone, as measured by a blood test called HbA1c that shows average blood sugar over several months. The study will also look at how these medications affect body weight, blood pressure, cholesterol levels, and other health measurements. Researchers want to understand if the combination medication works better than the individual medications at helping people reach target blood sugar levels and lose weight. The study will also measure how much time blood sugar levels stay within a healthy range using a continuous glucose monitor, which is a small device that tracks sugar levels throughout the day.

Participants will receive their assigned treatment for 68 weeks, with the entire study lasting about 75 weeks. During this time, they will have regular visits to check their blood sugar, weight, blood pressure, and overall health. The study will also ask participants questions about their quality of life and satisfaction with their diabetes treatment. Safety will be carefully monitored throughout the study, including checking for side effects and episodes of low blood sugar, which can occur when blood sugar drops too low and may cause symptoms like shakiness or confusion.

The purpose of the study is to see if empasiprubart can help improve the ability to perform daily activities compared to placebo. The study will also look at how safe the medication is and how well it is tolerated by people with this nerve condition. Researchers want to understand if this treatment can help reduce disability and improve quality of life for people living with this condition.

The study is divided into two parts and will last up to about two years for each person who takes part. During the study, empasiprubart will be given through a needle into a vein, which is called an infusion. People taking part will have regular visits where doctors will check their muscle strength, ability to perform daily tasks, grip strength, and overall well-being. The study will also measure various safety aspects including blood tests, heart function tests, and any side effects that may occur. Throughout the study, researchers will collect blood samples to measure the levels of the medication in the body and to see how the immune system responds to the treatment.

The purpose of this study is to learn about the safety and tolerability of two different treatment plans in people who have recently been diagnosed with Stage 3 Type 1 Diabetes, and to find out whether the study treatment can help slow down the loss of insulin-producing cells in the pancreas over time. The study will also look at how well blood sugar levels are controlled, including information gathered from devices that continuously monitor glucose.

During the study, participants will receive the treatment through intravenous administration, which means the medicine will be given directly into a vein. The treatment period will last for several months, and participants will be monitored regularly for any side effects or health problems that may occur. Doctors will also check how well the pancreas is working and measure insulin production throughout the study. The study is designed to compare different dose levels of SAB-142 with placebo to determine which approach works best and is safest for people with newly diagnosed Type 1 Diabetes.

The purpose of the study is to find out if AZD8205 works better than standard chemotherapy in slowing down cancer growth and helping people live longer. The study will look at how long people live without their cancer getting worse and how long they survive overall. It will also measure how many people respond to treatment, meaning their cancer shrinks or disappears, and how long these responses last.

During the study, people will be randomly assigned to receive either AZD8205 given through a vein or chemotherapy chosen by their doctor. AZD8205 is given as an infusion, which means it is slowly dripped into a vein over a period of time. The study will continue for several years and will track how well the treatments work and what side effects occur. People will have regular check-ups and scans to see how their cancer is responding to treatment and to monitor their overall health and quality of life.

The purpose of this study is to evaluate how safe the treatment is, how well it is tolerated by children, and whether it shows early signs of working to help with the condition. The study will look at whether the treatment causes any side effects or health problems and will also examine whether there are any early benefits for children with this syndrome. During the study, doctors will carefully monitor the children through various tests including blood tests, urine tests, tests of the fluid around the brain and spinal cord, heart monitoring with electrocardiogram and echocardiogram, brain wave recordings with electroencephalographic tests, and brain imaging with MRI scans. The study will also check for the presence of antibodies against the viral vector used to deliver the gene therapy.

The study involves giving a single dose of the gene therapy medicine through injection into both sides of the brain. Children participating in the study will need to live within one hour of the treatment center for at least four months after receiving the medicine, and this time period might be extended if any safety concerns arise. The children will be monitored closely with regular visits and tests to track their safety and any changes in their condition. Before receiving the treatment, children must have stable medication use for at least 28 days, and they cannot participate in any other research studies while enrolled in this one. The study is divided into two parts, with Part A including older children aged 6 to 12 years and Part B including younger children aged 2 to 12 years.

People taking part in this study will already be receiving treatment for their condition with either steroid medications taken by mouth or immunoglobulin therapy given through a vein or under the skin. During the study, participants will be checked regularly to see if their symptoms worsen or stay stable. The study will look at different measures of how well people can perform daily activities and how strong their muscles are, including grip strength in the dominant hand and overall muscle strength.

The study will last for several years and will involve multiple visits where various assessments will be done. The main focus will be on measuring whether people remain free from worsening of their condition over a period of 24 weeks. Other measurements will include changes in the ability to perform daily tasks, hand grip strength, and overall muscle strength at the same time point.

The study involves two groups of participants – one receiving rocatinlimab injections under the skin along with topical treatments, and another receiving placebo injections with the same topical treatments. The treatment period lasts for 24 weeks, during which the effectiveness of the medication will be evaluated by examining improvements in skin appearance and reduction in disease severity.

Throughout the study, doctors will monitor how well the treatment works by checking if participants’ skin becomes clearer and if their symptoms, such as itching and skin pain, improve. They will pay special attention to how the treatment affects different areas of the body, including the face and hands, in people who have atopic dermatitis in these locations.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

The main purpose of this research is to determine if patients who receive lidocaine during their colon cancer surgery need less pain medication (specifically opioid medications) in the first 24 hours after their operation. The study will also look at how quickly patients regain normal bowel function after surgery.

During the study, patients will receive either lidocaine or a sodium chloride solution (standard salt water) through an intravenous line. The treatment will be given during the surgical procedure and continue for a short time afterward. The amount of pain medication needed and the time until normal bowel function returns will be monitored after the surgery.

The study will use Dapagliflozin film-coated tablets containing 10 milligrams of the medication, which will be taken by mouth once daily. Some participants will receive the active medication, while others will receive a placebo. The treatment period will last for 78 weeks, during which the effects of the medication on heart health and kidney function will be monitored.

The main purpose of this research is to determine if adding this medication to regular blood pressure treatment can lower the risk of serious heart-related events, such as heart attacks, strokes, and kidney problems. The study will also look at how well the medication controls blood pressure and its effects on overall health and quality of life.

The purpose of this research is to determine if mezagitamab can reduce the amount of protein in the urine of people with Primary IgA Nephropathy. During the study, participants will receive either mezagitamab or placebo injections for up to 104 weeks (2 years). The medication or placebo will be given alongside their usual kidney disease treatments.

The study will monitor changes in kidney function and the amount of protein in participants’ urine throughout the treatment period. Researchers will also check for signs of improvement in other symptoms related to kidney disease, including the presence of blood in the urine. The study will track how well participants’ bodies respond to the treatment and measure the amount of medication in their blood.

The purpose of this study is to determine whether risankizumab is as effective as or more effective than vedolizumab for treating ulcerative colitis over a 48-week period. Participants in this study will have already tried other conventional treatments such as aminosalicylates (anti-inflammatory drugs), steroids, or immunomodulators without adequate relief of their symptoms.

During the study, participants will be randomly assigned to receive either risankizumab or vedolizumab. The study will monitor improvements in the intestinal lining through endoscopy (a procedure where a small camera is used to examine the inside of the colon) and track symptom improvement including stool frequency and rectal bleeding. This is an open-label study, meaning both the healthcare providers and participants will know which medication is being administered.

The main purpose of this research is to determine if empasiprubart is effective at improving muscle strength compared to intravenous immunoglobulin in people with Multifocal Motor Neuropathy. Both medications will be given through intravenous infusion, which means they are administered directly into a vein.

The study is divided into two parts. During the treatment period, participants will receive either empasiprubart or intravenous immunoglobulin along with their matching placebos. Throughout the study, doctors will measure changes in muscle strength and other aspects of the condition. The research team will also monitor the safety of the treatments and collect information about how well participants feel and function in their daily activities.

Participants in the trial will receive either masitinib or a placebo, both in combination with their standard ALS treatment. Masitinib is a type of medication known as a tyrosine kinase inhibitor, which works by blocking certain proteins that can contribute to disease progression. The trial will last for a period of 48 weeks, during which participants will take the medication orally in the form of coated tablets. The study will monitor changes in the participants’ condition and any side effects they may experience.

In addition to masitinib, some participants will continue taking another medication called Riluzole, which is commonly used in ALS treatment. The trial will compare the outcomes of those taking masitinib with those taking a placebo to determine the added benefits of masitinib. The goal is to provide more information on how masitinib can be used to improve the quality of life for people living with ALS.

The purpose of the study is to compare two approaches to hormone therapy: intermittent maximum androgen blockade (iMAB) and continuous maximum androgen blockade (cMAB). The study aims to determine the benefits and risks of these approaches in patients who have shown a significant response to initial hormone therapy. Participants will be randomly assigned to either continue their hormone therapy without interruption or to have breaks in their treatment. The study will monitor how long patients can go without restarting hormone therapy and compare the overall survival rates between the two groups.

Throughout the study, participants will be observed for changes in their quality of life, including physical functioning, sexual activity, and pain levels. The study will also track the time it takes for patients to need additional prostate cancer treatments and monitor their testosterone and PSA (prostate-specific antigen) levels. The trial will help determine if taking breaks in hormone therapy can maintain the same level of cancer control as continuous treatment while potentially improving the quality of life for patients.

The purpose of the study is to compare how these two treatments work in the body, their effects on the disease, and their safety. Participants will receive either ABP 692 or Ocrevus, and the study will monitor how the treatments affect the number of new active brain lesions, which are areas of damage in the brain that can be seen using a special imaging technique called MRI (Magnetic Resonance Imaging). The study will last for about 48 weeks, with regular check-ups to assess the treatments’ effects and safety.

Throughout the study, participants will receive regular infusions and undergo various assessments to monitor their health and the progression of their condition. The goal is to determine if ABP 692 is as effective and safe as Ocrevus in treating RRMS. This information could help improve treatment options for people living with this condition.

The purpose of the study is to evaluate how effective and safe the ICEF15 treatment is for people with fecal incontinence caused by problems with the external anal sphincter, a muscle that helps control bowel movements. Participants in the study will receive either the ICEF15 treatment or a placebo, which is a solution that does not contain the active treatment. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, to ensure unbiased results.

Throughout the study, participants will receive injections and will be monitored over a period of time to see if there is a reduction in the frequency of incontinence episodes. The study aims to determine if the treatment can reduce these episodes by at least 50% compared to before the treatment started. This research is important for finding new ways to help people manage fecal incontinence and improve their quality of life.

The purpose of the study is to determine if either duloxetine or furosemide can better control these types of pain over a period of three months. Participants will be randomly assigned to receive one of these medications or a placebo. The study will last for up to six months, during which participants will take the medication orally. The trial aims to assess changes in pain levels and overall quality of life using specific questionnaires designed to measure these aspects.

Throughout the study, participants will be monitored for any changes in their symptoms and overall health. The trial will also evaluate the safety of the medications by tracking any side effects or adverse events. The ultimate goal is to find supportive treatments that can help patients manage the side effects of their cancer therapy, thereby improving their quality of life during treatment.

The purpose of the study is to see if the combination of Vedolizumab and Upadacitinib can improve the health of people with moderately to severely active Crohn’s Disease more effectively than Vedolizumab alone. Participants will receive the treatment for a period of up to 52 weeks. Initially, both medications will be used together for a short period to see if they can quickly improve symptoms and the condition of the digestive tract. After this initial phase, the study will continue with Vedolizumab alone to maintain the improvements.

Throughout the study, participants will be monitored to assess their response to the treatment, focusing on both clinical symptoms and the condition of the digestive tract as seen through medical examinations. The study aims to provide valuable information on whether this dual therapy approach can offer better outcomes for individuals living with Crohn’s Disease.

The purpose of this study is to see how well Triumeq works in improving the overall survival of people with ALS over a period of 24 months. Participants will be randomly assigned to receive either Triumeq or the placebo. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations or bias.

Throughout the study, participants will have regular check-ups to monitor their health and assess the effects of the treatment. These check-ups will include evaluations of daily functioning, respiratory function, and overall quality of life. The study will also track any side effects or adverse events that may occur. The goal is to gather comprehensive information on how Triumeq affects people with ALS and to determine its safety and effectiveness in treating this condition.

The purpose of the study is to find new strategies to improve treatment for children with ALL. The study will look at how well these treatments work in improving survival rates and reducing complications. It will also explore the role of intensified treatment with pegaspargase and the impact of immunotherapy, which is a type of treatment that uses the body’s immune system to fight cancer, specifically using rituximab for patients with a subtype of ALL known as B-cell precursor ALL.

Participants in the study will receive either the study medication or a placebo. The study will monitor the participants over a period of time to assess the effectiveness and safety of the treatments. This includes checking for any side effects and measuring how the cancer responds to the treatment. The study aims to provide valuable information that could lead to better treatment options for children with ALL in the future.

Participants in the study will be randomly assigned to receive either Iptacopan or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will last for a total of 24 months, with an interim analysis at 9 months to assess the initial effects of the treatment.

Throughout the study, participants will have regular check-ups to monitor their health and the progression of their kidney disease. The main focus will be on measuring protein levels in the urine, which is an indicator of kidney function, and observing any changes in kidney function over time. The study aims to determine if Iptacopan can reduce protein levels in the urine and slow down the progression of IgA Nephropathy compared to the placebo. Participants will also be monitored for any side effects or adverse reactions to the treatment.

The purpose of the study is to evaluate how well lutikizumab works in reducing the symptoms of ulcerative colitis and to monitor any side effects. The study will involve both intravenous (IV) and subcutaneous (SC) forms of lutikizumab, meaning the medication will be administered either through a vein or under the skin. Participants will be monitored over a period of time to assess changes in their disease activity and any adverse events they may experience.

Throughout the study, participants will undergo regular assessments to track their progress. The study aims to determine the percentage of participants who show improvement in their condition by week 12. This includes looking at endoscopic improvement, which involves examining the inside of the colon, as well as clinical remission and response, which refer to the reduction or disappearance of symptoms. The study is expected to last for up to 52 weeks, providing valuable information on the long-term effects of lutikizumab in treating ulcerative colitis.

The purpose of the study is to evaluate how effective Atenativ is in helping patients who do not respond well to heparin. Participants in the study will receive either Atenativ or a placebo before their surgery. The study will monitor how well the treatment works in maintaining the patients’ response to heparin during the surgery. The study will also look at the safety of Atenativ and any side effects that may occur.

Throughout the study, participants will be closely monitored by medical professionals. The study will involve several visits and follow-ups to ensure the safety and well-being of the participants. The results of this study could provide valuable information on the use of Atenativ in patients with heparin resistance undergoing heart surgery.

The purpose of this study is to continue providing treatment to patients who have completed a previous cancer study with Olaparib and are still benefiting from it. The study aims to ensure the safety and tolerability of the ongoing treatment. Patients will continue to receive Olaparib if they are judged by their doctor to be benefiting from the treatment. The study will monitor the patients’ health and any side effects that may occur during the treatment period.

Participants in this study will take Olaparib tablets orally, with the treatment period lasting up to 123 days. The study will keep track of any serious side effects or important medical events that happen up to 30 days after the last dose of the study drug. This trial is designed to help patients who are already experiencing positive effects from Olaparib to continue their treatment safely.

The purpose of the study is to see if the combination of BI 690517 and empagliflozin is more effective than empagliflozin alone in helping people with heart failure. Participants in the study will be randomly assigned to receive either the combination of BI 690517 and empagliflozin or a placebo and empagliflozin. The study will last for a period of 42 days, during which participants will take the medications orally, meaning they will swallow them in the form of tablets.

Throughout the study, researchers will monitor participants to see how the treatment affects their heart failure symptoms and overall health. The main focus will be on the time it takes for a participant to experience a serious heart-related event, such as a heart-related death or hospitalization due to heart failure. The study aims to provide valuable information on whether the new combination treatment can improve outcomes for people living with heart failure.

The purpose of the study is to see how well JDQ443 works compared to docetaxel in controlling the cancer. Participants will receive either JDQ443 in tablet form or docetaxel through an intravenous infusion, which means it is given directly into a vein. Some participants may also receive a placebo, which looks like the real medication but does not contain any active ingredients. The study will monitor how long the cancer stays under control and will also look at overall survival rates, which means how long participants live after starting the treatment.

Throughout the study, participants will have regular check-ups to monitor their health and any side effects they might experience. The study will also collect information on how the treatments affect symptoms like chest pain, coughing, and shortness of breath. The trial is expected to continue until the end of 2025, and the results will help determine if JDQ443 is a better option for treating this type of lung cancer compared to the current standard treatment with docetaxel.

Participants in the study will take Letermovir tablets orally. The study will monitor the occurrence of early CMV infections or disease during the period when participants are taking the medication. Additionally, the study will observe the rates of certain blood conditions, such as leukopenia (a decrease in white blood cells) and neutropenia (a decrease in a type of white blood cell called neutrophils), during the treatment period. The study will also look at the occurrence of late CMV infections after stopping the medication and the body’s immune response over time.

The study will continue for a set period, and participants will be closely monitored throughout. The goal is to gather information on the effectiveness of Letermovir in preventing CMV infections and to understand any potential side effects or resistance to the treatment. This research aims to improve the care and outcomes for heart transplant recipients who are at risk of CMV infections.

The purpose of the study is to determine the effectiveness and safety of imlifidase in enabling kidney transplants for these patients. Participants will receive the treatment through an intravenous infusion, which means the medication is delivered directly into the bloodstream. The study will follow patients for one year after their transplant to monitor their health and the success of the transplant.

Throughout the study, researchers will assess various health indicators, such as kidney function and patient survival, to understand the impact of imlifidase. The study will also compare results with other groups of patients who have received kidney transplants without this treatment. This research aims to provide valuable insights into improving transplant outcomes for patients with high antibody levels.

The purpose of the study is to assess how effective efgartigimod is in treating TED by looking at the change in eye symptoms over a 24-week period. The study will involve regular check-ups and assessments to monitor the participants’ progress and any changes in their condition. The main focus will be on the reduction of eye bulging, known as proptosis, and improvements in the quality of life related to eye health. Participants will be randomly assigned to receive either the active treatment or the placebo, and neither the participants nor the researchers will know who is receiving which treatment during the study period.

Throughout the study, participants will be closely monitored for any side effects or changes in their condition. The study aims to provide valuable information on the safety and effectiveness of efgartigimod for people with TED, potentially leading to better treatment options in the future. The trial is expected to continue until 2027, with recruitment starting in 2024.

The study will determine which treatment is more effective at shrinking or controlling the tumor. Patients will be randomly assigned to receive either tovorafenib tablets or oral suspension taken by mouth, or standard chemotherapy medications given through an intravenous line (a small tube inserted into a vein). The study will measure how well tumors respond to treatment and how long patients remain free from tumor growth.

Doctors will regularly monitor patients using brain scans and medical examinations to track the tumor’s response to treatment. The study will continue for several years to gather long-term information about how well each treatment works and how it affects patients’ health over time. This research aims to help determine the most effective treatment option for children and young people with this specific type of brain tumor.